Bexsero (meningococcal group B vaccine) / GSK - LARVOL DELTA

The Impact of 4CMenB Vaccination and Doxycycline post-exposure prophylaxis on Pharyngeal Meningococcal Carriage among MSM using HIV PrEP (EACS 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease • Meningococcal Infections

Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada. (PubMed, Can Commun Dis Rep) - "Review of published studies and on-going trials with the four-component meningococcal serogroup B vaccine (4CMenB-Bexsero®)...Recommendations on the use of 4CMenB for individuals at high risk of gonorrhea infection have been issued in the United Kingdom and New York state based on results of observational studies. If results of observational studies are confirmed by randomized trials with an acceptable cost-effectiveness profile in the Canadian context, a targeted immunization program using 4CMenB could be implemented."

Clinical • Journal • Infectious Disease • Meningococcal Infections

Real-World Vaccine Effectiveness and Impact of the 4CMenB Vaccine in Infants, Children, and Adolescents: A Systematic Literature Review (IDWeek 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Review • Infectious Disease

Real-World 4CMenB Vaccine Duration of Protection in Infants and Children (IDWeek 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Antibody Persistence of the 4CMenB Vaccine in Infants: A Systematic Literature Review (IDWeek 2025) - No abstract available

Review • Infectious Disease

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - P1/2 | N=1215 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections

The 2025 UK 4CMenB vaccine programme for GBMSM at high risk of gonorrhoea. (PubMed, Sex Transm Infect) - No abstract available

Journal • Infectious Disease

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006). (PubMed, Vaccine) - "A two-dose regimen of ChAdOx1 nCoV-19 was immunogenic and safe in the trial population. No vaccine-related serious adverse events were reported. Immune responses persisted to 12 months in participants who did not experience breakthrough infection, This trial was registered with ISRCTN, trial number 15638344."

Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea (ANZCTR) - P2/3 | N=60 | Recruiting | Sponsor: Gold Coast University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

BIYELA - Bexsero Immunisation in Young Women in Africa (clinicaltrials.gov) - P3 | N=1100 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections

Direct whole-genome sequencing enables strain typing of unculturable Neisseria meningitidis from oropharyngeal carriage specimens. (PubMed, Microb Genom) - P=N/A, P4 | "Sequences were analysed using currently available bioinformatic tools, including the characterization of genogroup, multi-locus sequence typing (MLST), Bexsero Antigen Sequence Typing (BAST), porA and fetA type.Sensitivity of dWGS typing compared to WGS for genogroup, MLST, porA, fetA and BAST schemes was 88.89%, 72.22%, 100%, 94.44% and 88.24%, respectively...An alternative phylogenetic method (phylotyping) correctly predicted the clonal complex for 93.46% of the samples assessed. These results demonstrate that dWGS enables high-resolution molecular fine typing and can be applied to unculturable samples in N.m. carriage studies."

Journal • Infectious Disease • Meningococcal Infections

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov) - P3 | N=312 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Infectious Disease • Meningococcal Infections

Long-term protection against invasive meningococcal B disease and gonococcal infection five years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study. (PubMed, Clin Infect Dis) - "4CMenB demonstrates high protection against MenB disease in children and adolescents at 5 years. Moderate protection against the first and subsequent gonococcal infections in adolescents was observed up to 5 years post vaccination with waning evident after 5 years."

Journal • Observational data • Infectious Disease • Meningococcal Infections

[[Translated article]]New Prevention Measures in Venereology: Evidence Review on the DoxiPrEP/PEP Antibiotic and the 4CMenB Vaccine. (PubMed, Actas Dermosifiliogr) - "The most interesting one, based on the evidence obtained, is the use of doxycycline and meningococcal B vaccines. Specialists in dermatology and venereology must be informed about these new developments that may have an impact on the way in which STIs are managed worldwide. This is a scientific evidence review of these new interesting primary and secondary prevention strategies to control STIs in a high-risk population."

Journal • Review • Dermatology • Infectious Disease • Meningococcal Infections

ENHANCING CARE FOR SICKLE CELL PATIENTS WITH A REAL-TIME LONGITUDINAL PATIENT TRACKING FACILITY WITHIN AN ELECTRONIC PATIENT RECORD SYSTEM (EHA 2025) - "Of 156 patients, 25 left our care between June 2021 and December 2024, resulting in two cohorts of n1=81 and n2=131.Quality indicators were selected based on the Standards for Clinical Care of Adults with SCD in the UK (Sickle Cell Society, 2018).Data collection included hydroxyurea (HU) usage, and urine testing for albumin creatinine clearance (ACR) at each time point. Vaccination records were obtained from primary care for 129 patients (67 (2021) and 114 (2024)).Completeness of vaccination uptake was measured through uptake of influenza (annual), the bexsero (any time) and the pneumovax (within 5 years) of the two timepoints.To assess hospital workload over this period, we recorded cumulative A&E attendances, haematology day unit attendance, clinic appointments, number of nights in hospital and admissions from A&E.A&E attendances rose from 34 (2021) to 62(2024), HDU attendance from 10 (2021) to 81 (2024), number of nights in hospital from 170 (2021) to 355..."

Clinical • Genetic Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases • Sickle Cell Disease

Genomic surveillance of invasive Neisseria meningitidis isolates circulating in Paraguay, 2009-2021. (PubMed, Int Microbiol) - "This is the first genomic study of Neisseria meningitidis conducted in Paraguay, enabling a novel understanding of the genetic characteristics of invasive isolates. The generation of genomic data is essential for monitoring the spread of circulating lineages or clones that may alter their antigenic profiles to evade host immune responses."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections

A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov) - P3 | N=312 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • CNS Disorders • Infectious Disease • Meningococcal Infections

INVASIVE MENINGOCOCCAL DISEASE TREND IN PEDIATRIC POPULATION OF CHILE AFTER THE INTRODUCTION OF 4CMENB VACCINE FOR INFANTS (ESPID 2025) - "The impact of MCV-ACWY and 4CMenB has been significant in terms of the reduction in targeted population. Nevertheless, in order to make progress in the IMD control, it is essential that MCV-ACWY is included in adolescents, to achievie an indirect effect in other age-groups"

Clinical • Infectious Disease • Meningococcal Infections

MODELLING THE PUBLIC HEALTH IMPACT OF INTRODUCING 4CMENB VACCINATION AMONG INFANTS IN BRAZILIAN NATIONAL IMMUNIZATION PROGRAM (ESPID 2025) - "Additionally, MenW cases in 1-4-year-olds would be reduced by 42% due to cross-protection from the 4CMenB vaccine. Conclusions/Learning Points This modelling study demonstrated that the introduction of the 4CMenB vaccine can significantly provide a positive public health impact in Brazil by reducing both the morbidity and mortality associated with IMD."

Infectious Disease • Meningococcal Infections

USE OF 4CMENB IN ADOLESCENTS TO PREVENT INVASIVE MENINGOCOCCAL DISEASE (IMD) – ROBUST EVIDENCE FROM CLINICAL AND REAL-WORLD STUDIES CONDUCTED OVER ALMOST 20 YEARS (ESPID 2025) - "Conclusions/Learning Points Clinical and real-world evidence accumulated over ~20 years support 4CMenB vaccination to address the unmet medical need of protecting against IMD in adolescence...The two-dose (0, 1–2mo) flexible schedule and ability to use the same vaccine for infants/adolescents ensure ease of use. Wider adoption of adolescent vaccination programmes is warranted in line with IMD serogroup epidemiology."

Clinical • Real-world • Real-world evidence • Infectious Disease • Meningococcal Infections

PREDICTING THE DURATION OF PROTECTION OF 4CMENB VACCINE IN CHILDREN (ESPID 2025) - "Figure 1 Conclusions/Learning Points Estimated DoP of 4CMenB using 3-year data indicates longer-lasting protection than previously reported. However, the limited sample size and study length highlight the need for further research on the longevity of vaccine-induced immunity against IMD in children."

Clinical • Infectious Disease • Meningococcal Infections

B PART OF IT NT: ASSESSING THE EFFECTIVENESS OF 4CMENB AGAINST GONOCOCCAL INFECTION IN A LARGE TERRITORY-WIDE ADOLESCENT COHORT STUDY (ESPID 2025) - "However, the analysis could not account for differential exposure to gonorrhoea risk and uptake of diagnostic testing. A 4CMenB vaccine program has now been introduced in the Northern Territory for infants and adolescents."

Infectious Disease • Meningococcal Infections

0810 - INDUSTRY SYMPOSIUM 12 (NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT): Addressing Challenges & Solutions in Meningococcal Disease Prevention. (ESPID 2025) - "Bexsero (Meningococcal Group B Vaccine (rDNA, component, adsorbed)) is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. The impact of invasive disease in different age groups as well as the variability of antigen epidemiology for group B strains in different geographical areas should be considered when vaccinating. See section 5.1 for information on protection against specific group B strains. The use of this vaccine should be in accordance with official recommendations."

CME • Infectious Disease • Meningococcal Infections

Human monoclonal antibodies targeting subdominant meningococcal antigens confer cross-protection against gonococcus. (PubMed, Sci Transl Med) - "To determine antigens responsible for cross-protection, memory B cells isolated from 4CMenB-vaccinated volunteers were single cell-sorted to identify antibodies that kill gonococcus in a bactericidal assay...One of the PorB-specific antibodies provided protection in a mouse model of gonococcus infection. The identification of PorB and lipooligosaccharide as key antigens of gonococcal and meningococcal immunity provides a mechanistic explanation of the cross-protection observed in the clinic and shows that isolating human monoclonal antibodies from vaccinees can be instrumental for bacterial antigen discovery."

Journal • Infectious Disease • Meningococcal Infections

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants (clinicaltrials.gov) - P2 | N=724 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections